Decibel Therapeutics, Inc.

Decibel Therapeutics, Inc.

DBTX

DBTXDecibel Therapeutics, Inc. US flag

NASDAQ Global Select

4.91

USD

-0.04

- -

123.37MMarket Cap

Decibel Therapeutics, Inc.

DBTX

(NASDAQ Global Select)

Recent

price

4.91

P/E

ratio

- -

div

yld

- -

ROIC.AI

No data availableFinancial data will appear here once available

Capital Structure

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Revenue

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Similar Companies: Virios Therapeutics, Inc. (VIRI)
Novogene Co., Ltd. (688315.SS)
Biotest AG (BIESF)
Allarity Therapeutics, Inc. (ALLR)
MiMedx Group, Inc. (MDXG)
Mirati Therapeutics, Inc. (MRTX)
Business: Decibel Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing precision therapies to treat hearing loss and balance disorders. The company’s core products and services include gene therapy, small molecule therapeutics, and other biological treatments aimed at addressing inner ear disorders. Decibel Therapeutics develops novel therapeutics targeting the cellular and molecular mechanisms underlying hearing and balance dysfunction. Its pipeline comprises therapies designed for various forms of hearing loss, including noise-induced hearing loss, genetic hearing disorders, and age-related hearing decline. The company also provides research and development services in auditory science, leveraging proprietary platforms for drug discovery and validation. Decibel Therapeutics operates primarily in the biotechnology and pharmaceutical industry segments, targeting patients with auditory and vestibular conditions. It serves the global healthcare market with a focus on advanced therapeutic solutions for hearing impairments. Founded in 2015, the company is headquartered in Boston, Massachusetts, United States. Its recent major developments include strategic partnerships and collaborations to advance its therapies into clinical trials, as well as new funding rounds to support clinical and research activities. In the last 1-2 years, Decibel Therapeutics has launched new product candidates into clinical development and expanded its operational footprint to enhance drug discovery and development capabilities. The company operates worldwide with a focus on markets in North America, Europe, and other regions with significant unmet needs in hearing loss treatment. Decibel Therapeutics collaborates with academic institutions, pharmaceutical partners, and healthcare providers to accelerate the development and commercialization of its products. Its business model is centered on innovation in gene therapy and molecular medicine, aiming to transform the treatment landscape for patients with debilitating auditory disorders. This description captures Decibel Therapeutics’ comprehensive product offerings, its industry focus, recent strategic actions, and geographic operations, reflecting a formal, detailed overview consistent with financial data providers’ style.

Company News